Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics

International Journal of Psychiatry in Clinical Practice

Volumn 7, Issue 1, 2003, Pages 59-66

  De Nayer, A ^a   Windhager, E ^b   Irmansyah, ^c   Larmo, I ^d   Lindenbauer, B ^e   Rittmannsberger, H ^e   Platz, T ^f   Jones, A M ^g   Whiteford, J L ^g   Altman, C A ^g  

^a Sainte Therese Hospital   (Belgium)

^b Psychiatrische Klinik Wels   (Austria)

^c UNIVERSITY OF INDONESIA   (Indonesia)

^d Keskinen Terveyskeskus   (Finland)

^e KEPLER UNIVERSITY HOSPITAL   (Austria)

^f GENERAL HOSPITAL KLAGENFURT   (Austria)

^g ASTRAZENECA   (United Kingdom)

Author keywords

Atypical antipsychotic; Efficacy; Quetiapine; Schizophrenia; Tolerability

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGED; AGGRESSION; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSTILITY; HUMAN; INCIDENCE; MALE; MENTAL DISEASE; MOOD DISORDER; MULTICENTER STUDY; NEGATIVE SYNDROME; OPEN STUDY; PARKINSONISM; POSITIVE SYNDROME; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN;

EID: 0037358981     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500310001095     Document Type: Article

References (26)

1. Kane J (2001) Progress defined - short-term efficacy, long-term effectiveness. Int Clin Psychopharmacol 16(Suppl 1): S1-8.
2. Jibson MD, Tandon R (1998) New atypical antipsychotic medications. J Psychiatr Res 32: 215-28.
3. Stanniland C, Taylor D (2000) Tolerability of atypical antipsychotics. Drug Saf 22: 195-214.
4. Emsley RA (1999) Partial response to antipsychotic treatment: the patient with enduring symptoms. J Clin Psychiatry 60(Suppl 23): 10-3.
5. Weiden PJ, Aquila R, Dalheim L, Standard JM (1997) Switching antipsychotic medications. J Clin Psychiatry 58(Suppl 10): 63-72.
6. Kane JM (2001) Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 11(Suppl 4): S397-403.
7. Arana GW (2000) An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 61(Suppl 8): 5-11.
8. Emsley RA, Raniwalla J, Bailey PJ, Jones AM, on behalf of the PRIZE Study Group (2000) A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 15: 121-31.
9. Kane JM, Marder SR, Schooler NR et al (2001) Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 58: 965-72.
10. Masand PS, Berry SL (2000) Switching antipsychotic therapies. Ann Pharmacother 34: 200-7.
11. Barnes TRE, Joyce EM (2001) Antipsychotic drug treatment: recent advances. Curr Opin Psychiatry 14: 25-37.
12. Cutler AJ, Goldstein JM, Tumas JA (2002) Dosing and switching strategies for quetiapine fumarate. Clin Ther 24: 209-22
13. Arvanitis LA, Miller BG, and the Seroquel Trial 13 study group (1997) Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233-46.
14. Borison RL, Arvanitis LA, Miller BG, the US Seroquel Study Group (1996) ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16: 158-69.
15. Small JG, Hirsch SR, Arvanitis LA et al (1997) Quetiapine in patients with schizophrenia A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 54: 549-57
16. Kasper S, Müller-Spahn F (2000) Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 1: 783-801.
17. Brecher M, Rak IW, Westhead EK, Jones AM (2000) The long-term effect of quetiapine (Seroquel™) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 4: 287-91.
18. Still DJ, Dorson PG, Crismon ML, Pousson C (1996) Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 47: 1382-4.
19. Henderson DC, Nasrallah RA, Goff DC (1998) Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 59: 585-8.
20. Tollefson GD, Dellva MA, Mattler CA et al (1999) Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo The Collaborative Crossover Study Group. J Clin Psychopharmacol 19: 435-43.
21. Dossenbach MR, Kratky P, Schneidman M et al (2001) Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 62(Suppl 2): 28-34.
22. Klieser E, Lehmann E, Kinzler E et al (1995) Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 15: 45S-51S.
23. Tran PV, Hamilton SH, Kuntz AJ et al (1997) Double-blind comparison of olanzapine versus rispendone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychophar]macol 17: 407-18.
24. Conley RR, Mahmoud R (2001) A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 58: 765-74.
25. Mullen J, Jibson MD, Sweitzer D (2001) A comparison of the relative safety, efficacy, and and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 23: 1839-54.
26. Seroquel™ prescribing information (2001). 1-25.